Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Quivrin

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
European Urology Oncology|January 25, 2024
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)Bertrand F Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 15, 2026
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trialHugo Corda, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
European Urology Oncology|June 11, 2026
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate CancerQuentin Josset, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
Radiation Oncology (London, England)|August 22, 2022
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and AsiaBerend J Slotman, Mary Ann Clark, Enis Özyar, et al.
Clinical and Translational Radiation Oncology|March 27, 2023
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocolMaximilien Rogé, Yoann Pointreau, Paul Sargos, et al.
BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.
European Urology Oncology|February 7, 2025
Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter SeriesLudwige Abancourt, Muhammad Ali, Magali Quivrin, et al.
European Urology Oncology|January 23, 2026
Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective StudyGarvey Mezepo, Zine-Eddine Khene, Jihane Boustani, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
European Urology Oncology|January 25, 2024
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)Bertrand F Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 15, 2026
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trialHugo Corda, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
European Urology Oncology|June 11, 2026
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate CancerQuentin Josset, Audrey Blanc-Lapierre, Grégoire Pigne, et al.
Radiation Oncology (London, England)|August 22, 2022
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and AsiaBerend J Slotman, Mary Ann Clark, Enis Özyar, et al.
Clinical and Translational Radiation Oncology|March 27, 2023
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocolMaximilien Rogé, Yoann Pointreau, Paul Sargos, et al.
BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.
European Urology Oncology|February 7, 2025
Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter SeriesLudwige Abancourt, Muhammad Ali, Magali Quivrin, et al.
European Urology Oncology|January 23, 2026
Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective StudyGarvey Mezepo, Zine-Eddine Khene, Jihane Boustani, et al.
Pageof 3